Table 1.

Demographical data and number of analysed metastases for each patient enrolled in the study

Patient	Age at CT (years)	Sex	Primary cancer site	Number of analysed metastases	Lines of treatment	Chemotherapy regimens
1	77	F	Rectum	1	2	FOLFOX + bevacizumab FOLFIRI + cetuximab
2	66	M	Colon (left)	5	2	FOLFOX FOLFIRI + cetuximab
3	62	M	Colon (left)	3	4	FOLFIRI + cetuximab Regorafenib Trifluridine/tipiracil Capecitabine
4	59	M	Colon (left)	1	2	FOLFOX FOLFIRI + cetuximab
5	56	M	Rectum	1	2	FOLFIRI + cetuximab Not available
6	40	M	Colon (left)	2	2	FOLFOX + panitumumab FOLFIR I + bevacizumab
7	61	M	Colon (left)	4	2	FOLFOX + panitumumab FOLFIRI + aflibercept
8	56	M	Colon (right)	6	2	FOLFOX + panitumumab FOLFIRI + aflibercept
9	47	M	Colon (left)	5	2	FOLFOX + cetuximab FOLFIRI + bevacizumab
10	32	M	Colon (left)	7	3	FOLFOXIRI + bevacizumab FOLFIRI + aflibercept Panitumumab
11	66	M	Colon (left)	6	2	XELIRI FOLFOX + bevacizumab
12	63	F	Colon (left)	8	2	FOLFOX + panitumumab FOLFIRI + bevacizumab
13	61	F	Colon (left)	1	2	XELOX + bevacizumab FOLFIRI + cetuximab
14	52	M	Rectum	2	2	FOLFOX FOLFOX + bevacizumab
15	41	M	Colon (left)	5	1	FOLFOX + panitumumab
16	59	M	Rectum	4	1	FOLFIRI + bevacizumab
17	60	M	Colon (left)	9	3	FOLFOX + cetuximab FOLFIRI + bevacizumab FOLFIRI

Previous drug regimens are reported in chronological order of administration. All patients had histological-confirmed adenocarcinoma of the colon/rectum with metastatic liver disease not amenable to salvage surgery. In all cases, the primary tumour was KRAS (Kirsten rat sarcoma) wild-type and HER2 (human epidermal growth factor 2) positive

F Female, M Male, FOLFIRI Leucovorin + fluorouracil + irinotecan, FOLFOX Leucovorin + fluorouracil + oxaliplatin, FOLFOXIRI Leucovorin + fluorouracil + oxaliplatin + irinotecan, XELIRI Capecitabine + irinotecan, XELOX Capecitabine + oxaliplatin